New Delhi: In what comes as a serious reduction for the folks affected by Covid-19, the Central Government on Saturday slashed costs of the anti-viral drug Remdesivir by almost Rs 2,000 per injection.
Remdesivir will now be bought for as much less as Rs 899, as per the brand new listing introduced in a press word by Dr Vinod Kotwal, Member Advisor, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers.
ALSO READ |Â Delhi Covid Crisis: CM Kejriwal Informs Shortage Of Oxygen, ICU Beds As Capital Records Over 24,000 Cases In 24 Hrs
Below are the revised worth charges of the anti-viral drug:
- Cadila Healthcare Ltd REMDAC (from Rs 2,800 to Rs 899)
- Syngene International Ltd (Biocon Biologics India) RemWin (from Rs 3,950 to Rs 2,450)
- Reddy’s Laboratories Ltd REDYX from (Rs 5,400 to Rs 2,700)
- Hetero Healthcare Ltd COVIFOR from (Rs 5,400 to Rs 3,490)
- Cipla Ltd CIPREMI from (Rs 4,000 to Rs 3,000)
- Mylan Pharmaceuticals Pvt Ltd DESREM (from Rs 4,800 to Rs 3,400)
- Jubilant Generics Ltd JUBI-R from (Rs 4,700 to Rs 3,400)
The discount in worth comes amid the scarcity of Remdesivir following an unprecedented surge in Covid-19 instances within the nation.
ALSO READ |Â ‘Kumbh Mela Returnees Will Distribute Corona As Prasad’: Mumbai Mayor Demands Full Lockdown
The Centre earlier held a gathering with all-existing drug producers to debate the rise in manufacturing and provide and in addition to cut back the worth of Remdesivir injection as a number of states, together with the worst-affected Maharashtra, demanded ample provide of the anti-viral drug.
Earlier on April 11, the Centre prohibited exports of injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) until the covid scenario within the nation improves whereas initiating numerous steps to make sure easy accessibility of the anti-viral drug to sufferers and hospitals.
